Home Biosimilar Antibodies Immunology & Inflammation CD markers Mirzotamab (Anti-B7-H3 / CD276)
For research use only. Not for use in humans.

Mirzotamab (Anti-B7-H3 / CD276)

Synonyms: B7RP-2， B7-H3

Mirzotamab (Anti-B7-H3 / CD276) is a human IgG1κ monoclonal antibody targeting CD276/B7-H3. Mirzotamab is used to produce Mirzotamab clezutoclax antibody drug conjugate (ADC). MW: 144.86 KD.

Mirzotamab (Anti-B7-H3 / CD276)

Quality Control

Batch: A293501 Purity: 99% Protein concentration: 10.06mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Mirzotamab (Anti-B7-H3 / CD276) is a human IgG1κ monoclonal antibody targeting CD276/B7-H3. Mirzotamab is used to produce Mirzotamab clezutoclax antibody drug conjugate (ADC). MW: 144.86 KD.
References

Product Details

CAS No. 2229859-11-2
Molecular Weight 144.86
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07408063 RECRUITING Drug: GSK5764227|Drug: Dostarlimab Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma University Health Network, Toronto 2026-04-27 PHASE2
NCT05142189 RECRUITING Drug: Docetaxel|Drug: Carboplatin|Drug: Paclitaxel Non-Small Cell Lung Cancer BioNTech SE 2022-06-17 PHASE1
NCT04432649 NOT_YET_RECRUITING Solid Tumor Shenzhen Geno-Immune Medical Institute 2027-06-01 PHASE1; PHASE2
NCT04637503 NOT_YET_RECRUITING Neuroblastoma Shenzhen Geno-Immune Medical Institute 2026-12-31 PHASE1; PHASE2
NCT07231081 RECRUITING Solid Tumors Tcelltech Inc. 2025-10-16 PHASE1
NCT07189871 RECRUITING Drug: 177Lu-BetaBart Castration-Resistant Prostate Cancer (CRPC); Colorectal Cancer; NSCLC (Non-small Cell Lung Cancer); Ovarian Cancer; Cervical Cancer; Endometrial Cancer; TNBC, Triple Negative Breast Cancer; Small Cell Lung Cancer (SCLC ); Head &Amp; Neck Squamous Cell Carcinoma (HNSCC); Esophageal Squamous Cell Carcinoma (ESCC) Radiopharm Theranostics, Ltd 2026-02-23 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-04-29)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.